Related Experiment Video
Updated: Mar 9, 2026
07:13
Two Techniques to Create Hypoparathyroid Mice: Parathyroidectomy Using GFP Glands and Diphtheria-Toxin-Mediated Parathyroid Ablation
Published on: March 14, 2017
15.4K
MAJOR MOLECULAR GENETIC DRIVERS IN SPORADIC PRIMARY HYPERPARATHYROIDISM
1FARMINGTON, CONNECTICUT.
Transactions of the American Clinical and Climatological Association
|January 10, 2017
Summary
Primary hyperparathyroidism, often caused by parathyroid adenomas, involves genetic mutations. Key drivers include the cyclin D1 oncogene and MEN1 gene mutations, impacting both sporadic and familial cases.
Area of Science:
- Endocrinology
- Oncology
- Genetics
Background:
- Primary hyperparathyroidism typically results from a solitary parathyroid adenoma, but can involve multi-gland disease, carcinoma, or ectopic hormone production.
- While often sporadic, primary hyperparathyroidism has strong familial predispositions linked to known genetic mutations like MEN1, MEN2A, HJT, and FHH.
- Acquired mutations in sporadic hyperparathyroidism are also recognized.
Purpose of the Study:
- To review the most common and well-established genetic drivers of primary hyperparathyroidism.
- To highlight the roles of the cyclin D1 oncogene and the MEN1 gene in parathyroid neoplasia.
Main Methods:
- Literature review focusing on genetic mutations in primary hyperparathyroidism.
- Analysis of the established roles of cyclin D1 and MEN1 gene mutations.
Main Results:
- The oncogene cyclin D1's role in neoplasia was first identified in parathyroid adenomas.
- Somatic mutations of the MEN1 gene are found in a significant portion of non-familial parathyroid adenomas.
Conclusions:
- Cyclin D1 and MEN1 gene mutations are critical genetic drivers in primary hyperparathyroidism.
- Understanding these genetic underpinnings is crucial for both sporadic and familial forms of the disease.
Related Concept Videos
00:59The Parathyroid Glands
5.6K
The two pairs of parathyroid glands embedded within the posterior surface of the thyroid gland are restricted by a dense capsule around them. These glands comprise two distinct cell populations—parathyroid oxyphil and parathyroid principal cells- pivotal in calcium homeostasis.
Oxyphil cells, whose functions remain elusive, emerge during late puberty, adding a layer of complexity to the parathyroid gland's intricacies. In contrast, principal parathyroid cells undertake a vital role by...
Oxyphil cells, whose functions remain elusive, emerge during late puberty, adding a layer of complexity to the parathyroid gland's intricacies. In contrast, principal parathyroid cells undertake a vital role by...
5.6K
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
60
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
60
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
85
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
85
01:29Pharmacogenomics: Identification of New Drug Targets
57
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
57
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
77
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
77
01:27Principles of Pharmacogenetics: Types of Genetic Variants
68
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
68